Clinical Trial Update: Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of B-VEC for treating Dystrophic Epidermolysis Bullosa has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dominant Dystrophic Epidermolysis Bullosa
• Dystrophic Epidermolysis Bullosa
• Recessive Dystrophic Epidermolysis Bullosa

Drugs mentioned

• B-VEC (null)

Snippet

Sponsor: Krystal Biotech, Inc. | Conditions: Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Status: COMPLETED | Results posted: 2023-02-17